Structure-function of cytoprotective coagulation proteases and their receptors View Homepage


Ontology type: schema:MonetaryGrant     


Grant Info

YEARS

2010-2019

FUNDING AMOUNT

3789491 USD

ABSTRACT

? DESCRIPTION (provided by applicant): This application seeks to improve basic understanding of the molecular mechanisms that mediate cytoprotective actions of coagulation proteases on cells. Available therapeutic solutions for vascular, thrombotic, and inflammatory diseases are limited and mortality rates remain unacceptably high. Activated protein C (APC) has beneficial effects of in a broad spectrum of injury and disease models where ischemia and inflammation contribute to pathogenesis. The cytoprotective activities of APC are responsible for these beneficial effects of APC in vivo and involve the endothelial protein C receptor (EPCR), protease activated receptor (PAR) 1, and PAR3. The cytoprotective effects of APC on cells contrast with proinflammatory effects of other coagulation proteases (e.g. thrombin) on cells and initiated novel perspectives on how the same receptor (PAR1) can mediate such different opposing effects. The EPCR-dependent non-canonical activation of PAR1 at Arg46 and PAR3 at Arg41 are newly discovered mechanisms of biased PAR signaling. The functional selectivity of thrombin versus APC is thus determined by the proteolytic activation sites in PAR1 and PAR3 that give rise to the new N-terminal tethered-ligands. The immediate goal of this application is to gain novel insights into the molecular mechanisms of non-canonical biased PAR signaling and the extent to which the canonical/non-canonical PAR profile determines the functional selectivity of proteases. Major focus will be on structure-function studies of PAR3 non-canonical signaling mechanisms and of PAR canonical/non- canonical proteolysis profiles of coagulation proteases. Furthermore, several conceptual key aspects of the non-canonical PAR activation and biased signaling paradigm will be tested in vitro and in vivo using engineered EPCR variants that are expected to augment cytoprotective mechanisms. The long-term objectives of this application are to contribute to diagnostic and therapeutic progress for vascular, thrombotic, and inflammatory diseases by advancing knowledge through both basic and translational research. Novel hypotheses will be tested using biochemical and cellular biology methods and validated by studies in mouse models in vivo. The specific aims are: 1) To characterize the structure-activity-function determinants for EPCR- dependent non-canonical PAR1 and PAR3 activation, and 2) To provide proof-of-concept for optimized engineered EPCR variants with improved characteristics. Successful completion of the proposed studies will increase our knowledge and understanding of vascular, thrombotic, and inflammatory diseases and may provide a platform for the development of novel therapeutic strategies for a variety of disorders in which thrombosis, apoptosis and inflammation contribute to pathogenesis. More... »

URL

http://projectreporter.nih.gov/project_info_description.cfm?aid=9390486

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2206", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "amount": {
      "currency": "USD", 
      "type": "MonetaryAmount", 
      "value": "3789491"
    }, 
    "description": "? DESCRIPTION (provided by applicant): This application seeks to improve basic understanding of the molecular mechanisms that mediate cytoprotective actions of coagulation proteases on cells. Available therapeutic solutions for vascular, thrombotic, and inflammatory diseases are limited and mortality rates remain unacceptably high. Activated protein C (APC) has beneficial effects of in a broad spectrum of injury and disease models where ischemia and inflammation contribute to pathogenesis. The cytoprotective activities of APC are responsible for these beneficial effects of APC in vivo and involve the endothelial protein C receptor (EPCR), protease activated receptor (PAR) 1, and PAR3. The cytoprotective effects of APC on cells contrast with proinflammatory effects of other coagulation proteases (e.g. thrombin) on cells and initiated novel perspectives on how the same receptor (PAR1) can mediate such different opposing effects. The EPCR-dependent non-canonical activation of PAR1 at Arg46 and PAR3 at Arg41 are newly discovered mechanisms of biased PAR signaling. The functional selectivity of thrombin versus APC is thus determined by the proteolytic activation sites in PAR1 and PAR3 that give rise to the new N-terminal tethered-ligands. The immediate goal of this application is to gain novel insights into the molecular mechanisms of non-canonical biased PAR signaling and the extent to which the canonical/non-canonical PAR profile determines the functional selectivity of proteases. Major focus will be on structure-function studies of PAR3 non-canonical signaling mechanisms and of PAR canonical/non- canonical proteolysis profiles of coagulation proteases. Furthermore, several conceptual key aspects of the non-canonical PAR activation and biased signaling paradigm will be tested in vitro and in vivo using engineered EPCR variants that are expected to augment cytoprotective mechanisms. The long-term objectives of this application are to contribute to diagnostic and therapeutic progress for vascular, thrombotic, and inflammatory diseases by advancing knowledge through both basic and translational research. Novel hypotheses will be tested using biochemical and cellular biology methods and validated by studies in mouse models in vivo. The specific aims are: 1) To characterize the structure-activity-function determinants for EPCR- dependent non-canonical PAR1 and PAR3 activation, and 2) To provide proof-of-concept for optimized engineered EPCR variants with improved characteristics. Successful completion of the proposed studies will increase our knowledge and understanding of vascular, thrombotic, and inflammatory diseases and may provide a platform for the development of novel therapeutic strategies for a variety of disorders in which thrombosis, apoptosis and inflammation contribute to pathogenesis.", 
    "endDate": "2019-11-30T00:00:00Z", 
    "funder": {
      "id": "https://www.grid.ac/institutes/grid.279885.9", 
      "type": "Organization"
    }, 
    "id": "sg:grant.2543001", 
    "identifier": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "2543001"
        ]
      }, 
      {
        "name": "nih_id", 
        "type": "PropertyValue", 
        "value": [
          "R01HL104165"
        ]
      }
    ], 
    "inLanguage": [
      "en"
    ], 
    "keywords": [
      "functional selectivity", 
      "pathogenesis", 
      "translational research", 
      "PAR1", 
      "other coagulation proteases", 
      "variety", 
      "ischemia", 
      "concept", 
      "apoptosis", 
      "cytoprotective activity", 
      "long-term objective", 
      "disorders", 
      "cytoprotective effect", 
      "cytoprotective action", 
      "novel insights", 
      "development", 
      "knowledge", 
      "specific aim", 
      "non-canonical biased PAR", 
      "rise", 
      "novel hypothesis", 
      "extent", 
      "major focus", 
      "coagulation proteases", 
      "same receptor", 
      "Available therapeutic solutions", 
      "disease models", 
      "canonical proteolysis profiles", 
      "Arg46", 
      "EPCR-dependent non-canonical activation", 
      "novel perspective", 
      "novel", 
      "terminal", 
      "cell contrast", 
      "APC", 
      "function determinants", 
      "inflammation", 
      "thrombosis", 
      "cytoprotective coagulation proteases", 
      "Par3", 
      "molecular mechanisms", 
      "PAR3 activation", 
      "biased PAR", 
      "several conceptual key aspects", 
      "therapeutic progress", 
      "mortality rate", 
      "understanding", 
      "endothelial protein C receptor", 
      "mouse model", 
      "PAR3 non-canonical signaling mechanisms", 
      "thrombin", 
      "platform", 
      "immediate goal", 
      "description", 
      "protein C", 
      "applicants", 
      "effect", 
      "mechanism", 
      "characteristics", 
      "cellular biology methods", 
      "injury", 
      "dependent non-canonical PAR1", 
      "cells", 
      "proinflammatory effects", 
      "canonical PAR profile", 
      "application", 
      "protease", 
      "Arg41", 
      "successful completion", 
      "receptors", 
      "structure-function", 
      "broad spectrum", 
      "paradigm", 
      "beneficial effects", 
      "proteolytic activation site", 
      "vitro", 
      "proof", 
      "study", 
      "par", 
      "structure-function studies", 
      "non-canonical PAR activation", 
      "basic understanding", 
      "structure-activity", 
      "cytoprotective mechanisms", 
      "therapeutic strategies", 
      "inflammatory diseases", 
      "EPCR variants", 
      "vivo"
    ], 
    "name": "Structure-function of cytoprotective coagulation proteases and their receptors", 
    "recipient": [
      {
        "id": "https://www.grid.ac/institutes/grid.214007.0", 
        "type": "Organization"
      }, 
      {
        "affiliation": {
          "id": "https://www.grid.ac/institutes/grid.214007.0", 
          "name": "SCRIPPS RESEARCH INSTITUTE", 
          "type": "Organization"
        }, 
        "familyName": "MOSNIER", 
        "givenName": "LAURENT OLIVIER", 
        "id": "sg:person.0744746771.44", 
        "type": "Person"
      }, 
      {
        "member": "sg:person.0744746771.44", 
        "roleName": "PI", 
        "type": "Role"
      }
    ], 
    "sameAs": [
      "https://app.dimensions.ai/details/grant/grant.2543001"
    ], 
    "sdDataset": "grants", 
    "sdDatePublished": "2019-03-07T11:59", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com.uberresearch.data.processor/core_data/20181219_192338/projects/base/nih_projects_10.xml.gz", 
    "startDate": "2010-07-01T00:00:00Z", 
    "type": "MonetaryGrant", 
    "url": "http://projectreporter.nih.gov/project_info_description.cfm?aid=9390486"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/grant.2543001'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/grant.2543001'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/grant.2543001'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/grant.2543001'


 

This table displays all metadata directly associated to this object as RDF triples.

132 TRIPLES      19 PREDICATES      110 URIs      102 LITERALS      5 BLANK NODES

Subject Predicate Object
1 sg:grant.2543001 schema:about anzsrc-for:2206
2 schema:amount Nb5f383ad1fe0458b8ae0e2d33af74a07
3 schema:description ? DESCRIPTION (provided by applicant): This application seeks to improve basic understanding of the molecular mechanisms that mediate cytoprotective actions of coagulation proteases on cells. Available therapeutic solutions for vascular, thrombotic, and inflammatory diseases are limited and mortality rates remain unacceptably high. Activated protein C (APC) has beneficial effects of in a broad spectrum of injury and disease models where ischemia and inflammation contribute to pathogenesis. The cytoprotective activities of APC are responsible for these beneficial effects of APC in vivo and involve the endothelial protein C receptor (EPCR), protease activated receptor (PAR) 1, and PAR3. The cytoprotective effects of APC on cells contrast with proinflammatory effects of other coagulation proteases (e.g. thrombin) on cells and initiated novel perspectives on how the same receptor (PAR1) can mediate such different opposing effects. The EPCR-dependent non-canonical activation of PAR1 at Arg46 and PAR3 at Arg41 are newly discovered mechanisms of biased PAR signaling. The functional selectivity of thrombin versus APC is thus determined by the proteolytic activation sites in PAR1 and PAR3 that give rise to the new N-terminal tethered-ligands. The immediate goal of this application is to gain novel insights into the molecular mechanisms of non-canonical biased PAR signaling and the extent to which the canonical/non-canonical PAR profile determines the functional selectivity of proteases. Major focus will be on structure-function studies of PAR3 non-canonical signaling mechanisms and of PAR canonical/non- canonical proteolysis profiles of coagulation proteases. Furthermore, several conceptual key aspects of the non-canonical PAR activation and biased signaling paradigm will be tested in vitro and in vivo using engineered EPCR variants that are expected to augment cytoprotective mechanisms. The long-term objectives of this application are to contribute to diagnostic and therapeutic progress for vascular, thrombotic, and inflammatory diseases by advancing knowledge through both basic and translational research. Novel hypotheses will be tested using biochemical and cellular biology methods and validated by studies in mouse models in vivo. The specific aims are: 1) To characterize the structure-activity-function determinants for EPCR- dependent non-canonical PAR1 and PAR3 activation, and 2) To provide proof-of-concept for optimized engineered EPCR variants with improved characteristics. Successful completion of the proposed studies will increase our knowledge and understanding of vascular, thrombotic, and inflammatory diseases and may provide a platform for the development of novel therapeutic strategies for a variety of disorders in which thrombosis, apoptosis and inflammation contribute to pathogenesis.
4 schema:endDate 2019-11-30T00:00:00Z
5 schema:funder https://www.grid.ac/institutes/grid.279885.9
6 schema:identifier N2001f4ec17d54f5a843f85dc89295d71
7 N3a2e2b721a3041af9a2b9cf07f681db8
8 schema:inLanguage en
9 schema:keywords APC
10 Arg41
11 Arg46
12 Available therapeutic solutions
13 EPCR variants
14 EPCR-dependent non-canonical activation
15 PAR1
16 PAR3 activation
17 PAR3 non-canonical signaling mechanisms
18 Par3
19 apoptosis
20 applicants
21 application
22 basic understanding
23 beneficial effects
24 biased PAR
25 broad spectrum
26 canonical PAR profile
27 canonical proteolysis profiles
28 cell contrast
29 cells
30 cellular biology methods
31 characteristics
32 coagulation proteases
33 concept
34 cytoprotective action
35 cytoprotective activity
36 cytoprotective coagulation proteases
37 cytoprotective effect
38 cytoprotective mechanisms
39 dependent non-canonical PAR1
40 description
41 development
42 disease models
43 disorders
44 effect
45 endothelial protein C receptor
46 extent
47 function determinants
48 functional selectivity
49 immediate goal
50 inflammation
51 inflammatory diseases
52 injury
53 ischemia
54 knowledge
55 long-term objective
56 major focus
57 mechanism
58 molecular mechanisms
59 mortality rate
60 mouse model
61 non-canonical PAR activation
62 non-canonical biased PAR
63 novel
64 novel hypothesis
65 novel insights
66 novel perspective
67 other coagulation proteases
68 par
69 paradigm
70 pathogenesis
71 platform
72 proinflammatory effects
73 proof
74 protease
75 protein C
76 proteolytic activation site
77 receptors
78 rise
79 same receptor
80 several conceptual key aspects
81 specific aim
82 structure-activity
83 structure-function
84 structure-function studies
85 study
86 successful completion
87 terminal
88 therapeutic progress
89 therapeutic strategies
90 thrombin
91 thrombosis
92 translational research
93 understanding
94 variety
95 vitro
96 vivo
97 schema:name Structure-function of cytoprotective coagulation proteases and their receptors
98 schema:recipient Ne6ec1d7006a14016b7c6fb7bde23c7ba
99 sg:person.0744746771.44
100 https://www.grid.ac/institutes/grid.214007.0
101 schema:sameAs https://app.dimensions.ai/details/grant/grant.2543001
102 schema:sdDatePublished 2019-03-07T11:59
103 schema:sdLicense https://scigraph.springernature.com/explorer/license/
104 schema:sdPublisher Nfc838db122f549fbbb3d369991b2388f
105 schema:startDate 2010-07-01T00:00:00Z
106 schema:url http://projectreporter.nih.gov/project_info_description.cfm?aid=9390486
107 sgo:license sg:explorer/license/
108 sgo:sdDataset grants
109 rdf:type schema:MonetaryGrant
110 N2001f4ec17d54f5a843f85dc89295d71 schema:name dimensions_id
111 schema:value 2543001
112 rdf:type schema:PropertyValue
113 N3a2e2b721a3041af9a2b9cf07f681db8 schema:name nih_id
114 schema:value R01HL104165
115 rdf:type schema:PropertyValue
116 Nb5f383ad1fe0458b8ae0e2d33af74a07 schema:currency USD
117 schema:value 3789491
118 rdf:type schema:MonetaryAmount
119 Ne6ec1d7006a14016b7c6fb7bde23c7ba schema:member sg:person.0744746771.44
120 schema:roleName PI
121 rdf:type schema:Role
122 Nfc838db122f549fbbb3d369991b2388f schema:name Springer Nature - SN SciGraph project
123 rdf:type schema:Organization
124 anzsrc-for:2206 schema:inDefinedTermSet anzsrc-for:
125 rdf:type schema:DefinedTerm
126 sg:person.0744746771.44 schema:affiliation https://www.grid.ac/institutes/grid.214007.0
127 schema:familyName MOSNIER
128 schema:givenName LAURENT OLIVIER
129 rdf:type schema:Person
130 https://www.grid.ac/institutes/grid.214007.0 schema:name SCRIPPS RESEARCH INSTITUTE
131 rdf:type schema:Organization
132 https://www.grid.ac/institutes/grid.279885.9 schema:Organization
 




Preview window. Press ESC to close (or click here)


...